



PSORIASIS

SECUKINUMAB PROVIDES COMPREHENSIVE LONG-TERM TREATMENT ACROSS MULTIPLE MANIFESTATIONS OF PSORIATIC DISEASE

Richard Langley⁽¹⁾ - Kristian Reich⁽²⁾ - Robert Bissonnette⁽³⁾ - Alice Gottlieb⁽⁴⁾ - Helena Marzo-ortega⁽⁵⁾ - Gabriele Dicomite⁽⁶⁾ - Maher Aassi⁽⁶⁾ - Philip Mease⁽⁷⁾

Dalhousie University, Division Of Dermatology, Department Of Medicine, Halifax, Nova Scotia, Canada⁽¹⁾ - Institute For Health Services Research In Dermatology And Nursing, University Medical Center Hamburg-eppendorf, Dermatology, Hamburg, Germany⁽²⁾ - Innovaderm Research, Dermatology, Montreal, Canada⁽³⁾ - , Icahn School Of Medicine At Mount Sinai, New York, Dermatology, New York, United States⁽⁴⁾ - Nihl Lbrc, Ltht And Lirrm, Uol, Rheumatic And Musculoskeletal Medicine, Leeds, United Kingdom⁽⁵⁾ - Novartis Pharma Ag, Pharma, Basel, Switzerland⁽⁶⁾ - Swedish Medical Center And University Of Washington, Dermatology, Seattle, United States⁽⁷⁾

Introduction and Objective: Secukinumab is a fully human monoclonal antibody that selectively neutralises IL-17A, a cornerstone cytokine involved in the development of psoriatic disease. Here we report the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease including, moderate-to-severe plaque-type, nail and palmoplantar psoriasis; psoriatic arthritis and ankylosing spondylitis.

Materials and Methods: Data are presented from key Phase 3, randomised, double-blind trials of secukinumab (SCULPTURE, ERASURE/FIXTURE, TRANSFIGURE, GESTURE, FUTURE 2 and MEASURE 2) in 1872 patients. Outcome measures include Psoriasis Area and Severity Index (PASI) 75/90/100, Nail Psoriasis Severity Index (NAPSI), palmoplantar Investigator's Global Assessment (ppIGA), American College of Rheumatology response criteria (ACR) 20 and Assessment of SpondyloArthritis International Society (ASAS) 20/40 response.

Results: In SCULPTURE, secukinumab 300mg treatment delivered high levels of skin clearance with the PASI 75/90/100 responses at Year 1 (88.9%, 68.5%, and 43.8%; n=162), maintained at Year 5 (88.5%, 66.4%, and 41%; n=122). Similarly, in ERASURE/FIXTURE, PASI 75/90/100 responses at Year 1 (99.4%, 83.5%, and 52.6%; n=363) were maintained to Year 5 (85.1%, 67.2%, and 37.8%; n=262). The sustainability of efficacy in nail psoriasis was demonstrated in TRANSFIGURE (NAPSI improvement at 2.5 years: -73.3% [300mg], -63.6% [150mg]) and in palmoplantar psoriasis in GESTURE (ppIGA 0/1 responders at 2.5 years: 59.2% [300mg], 52.5% [150mg]). In FUTURE 2, ACR 20 responses in 300mg and 150mg dose groups at Year 1 (72.7% [n=88] and 72.7%





[n=88]) were sustained or further improved at Year 4 (71.2% [n=73] and 75.0% [n=72]), respectively. In MEASURE 2, ASAS 20/40 responses at Year 1 (74.2% and 57.0%, n=93) were sustained at Year 4 (73.3% and 60.5%, n=86) with 150mg dose. Secukinumab demonstrated favourable safety profile across studies, with no increase in adverse events over time.

Conclusions: Secukinumab provides effective long-term treatment across multiple manifestations of psoriatic disease.

